Suppr超能文献

微小RNA-375在人结直肠癌血浆和组织中的表达是匹配的。

The expression of microRNA-375 in plasma and tissue is matched in human colorectal cancer.

作者信息

Xu Lingling, Li Minzhe, Wang Min, Yan Dong, Feng Guosheng, An Guangyu

机构信息

Department of Oncology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China.

出版信息

BMC Cancer. 2014 Sep 25;14:714. doi: 10.1186/1471-2407-14-714.

Abstract

BACKGROUND

MicroRNAs (miRNAs) offer great potential as cancer biomarkers. The importance of miRNAs profiling in tissue and body fluids in colorectal cancer (CRC) have been addressed respectively in many studies. The purpose of our study is to systematically assess the expression of miRNAs in cancer tissue and matched plasma samples and to evaluate their usefulness as minimally invasive diagnostic biomarkers for the detection of CRC.

METHODS

The study was divided into two phases: firstly, qRT-PCR based TaqMan Low Density MiRNA Arrays (TLDAs) was used to screen the differentially expressed miRNAs in 6 plasma samples of CRC patients and 6 healthy controls. Secondly, marker validation by stem-loop reverse transcription real-time PCR using an independent set of paired cancer tissues (n=88) and matched plasma samples (CRC, n=88; control, n=40). Correlation analysis was determined by Pearson's test. Receiver operating characteristic curve analyses were applied to obtain diagnostic utility of the differentially expressed miRNAs. Target gene prediction and signal pathway analyses were used to predict the function of miRNAs.

RESULTS

TLDAs identified 42 miRNAs, which were differentially expressed in patients and healthy individuals. Five of them (miR-375, miR-150, miR-206, miR-125b and miR-126*) were chosen to be validated in plasma and tissue samples. The results indicated that for plasma sample, miR-375 (p<0.0001) and miR-206 (p=0.0002) were dysregulated and could discriminate CRC patients from healthy controls. For tissue samples, miR-375 (p<0.0001), miR-150 (p<0.0001), miR-125b (p=0.0065) and miR-126*(p=0.0009) were down-regulated. miR-375 was significantly down-regulated and positively correlated in both tissue and plasma samples (r=0.4663, p=0.0007). Gene ontology and signal pathway analyses showed that most of the target genes that were regulated by miR-375 were involved in some critical pathways in the development and progression of cancer.

CONCLUSIONS

Our results indicate that the down-regulation of miR-375 in plasma and tissue is matched in CRC. Moreover, bioinformatics prediction revealed miR-375 association with some critical signal pathways in the development and progression of CRC. Therefore, plasma miR-375 holds great promise to be an alternative tissue biomarker for CRC detection.

摘要

背景

微小RNA(miRNA)作为癌症生物标志物具有巨大潜力。许多研究分别探讨了miRNA谱在结直肠癌(CRC)组织和体液中的重要性。本研究的目的是系统评估miRNA在癌组织和配对血浆样本中的表达,并评估其作为CRC检测的微创诊断生物标志物的效用。

方法

本研究分为两个阶段:首先,基于qRT-PCR的TaqMan低密度miRNA阵列(TLDA)用于筛选6例CRC患者血浆样本和6例健康对照中差异表达的miRNA。其次,使用独立的配对癌组织(n = 88)和配对血浆样本(CRC,n = 88;对照,n = 40)通过茎环逆转录实时PCR进行标志物验证。相关性分析通过Pearson检验确定。应用受试者工作特征曲线分析以获得差异表达miRNA的诊断效用。使用靶基因预测和信号通路分析来预测miRNA的功能。

结果

TLDA鉴定出42种在患者和健康个体中差异表达的miRNA。其中5种(miR-375、miR-150、miR-206、miR-125b和miR-126*)被选择在血浆和组织样本中进行验证。结果表明,对于血浆样本,miR-375(p<0.0001)和miR-206(p = 0.0002)表达失调,可区分CRC患者和健康对照。对于组织样本,miR-375(p<0.0001)、miR-150(p<0.0001)、miR-125b(p = 0.0065)和miR-126*(p = 0.0009)下调。miR-375在组织和血浆样本中均显著下调且呈正相关(r = 0.4663,p = 0.0007)。基因本体和信号通路分析表明,受miR-375调控的大多数靶基因参与了癌症发生发展的一些关键通路。

结论

我们的结果表明,CRC中血浆和组织中miR-375的下调是一致的。此外,生物信息学预测揭示了miR-375与CRC发生发展中的一些关键信号通路相关。因此,血浆miR-375有望成为CRC检测的替代组织生物标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a6fa/4181388/057ff294a668/12885_2014_4880_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验